JCJiamei Chen

Jiamei Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiamei Chen has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Ping Liu

    Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    27 shared publications
  • Wei Liu

    Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    19 shared publications
  • Yongping Mu

    Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    17 shared publications
  • Hua Zhang

    Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    15 shared publications
  • Yadong Fu

    Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    11 shared publications
  • Xiaoxi Zhou

    Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    10 shared publications

Latest Publications

  • Open Access

    Activation of hepatic USP5 as a novel strategy to ameliorate metabolic dysfunction-associated steatotic liver disease by deubiquitinating CPT-1A

    by Feng Qin, Qinmei Sun, Jiamei Chen, Guanghao Zhu, Siting Gao, Yidan Shang, Yaoshan Zhou, Xin Xin, Kai Huang, Rutao Lin, et al.

    Ubiquitin-specific protease 5 (USP5) is a key regulator in cancer, pain, and inflammatory disorders, yet its role in metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely unexplored. This study aims to elucidate the functional significance and therapeutic potential of USP5 in MASLD. Hepatic USP5 expression was markedly reduced in liver specimens from MASLD patients, as well as in relevant in vivo and in vitro models. Hepatocyte-specific genetic ablation of USP5 exacerbated MASLD-associated hepatic steatosis and inflammation, whereas USP5 overexpression alleviated steatohepatitis. Mechanistically, co-immunoprecipitation coupled with mass spectrometry (Co-IP-MS), surface plasmon resonance (SPR), and ubiquitination assays revealed that USP5 directly interacts with carnitine palmitoyltransferase 1A (CPT-1A) and selectively cleaves K6-linked ubiquitin chains, thereby stabilizing CPT-1A via deubiquitination. In the context of MASLD, reduced USP5 expression disrupts this deubiquitination process, accelerating proteasomal degradation of CPT-1A. Consequently, USP5 deficiency impairs mitochondrial fatty acid oxidation (FAO) and promotes hepatic lipid accumulation. Notably, hepatocyte-specific restoration of CPT-1A substantially rescued the exacerbated lipid deposition induced by USP5 deficiency. Furthermore, docking-based virtual screening coupled with in vivo validation identified ligustroflavone (LF) as a potent USP5 activator. Animal studies clearly demonstrated that LF robustly enhanced USP5-mediated CPT-1A stabilization and significantly ameliorated lipid accumulation and inflammation inMASLD mice. Collectively, our findings uncover a previously unrecognized ubiquitination regulatory axis centered on USP5 and CPT-1A, and establish hepatic USP5 as an emerging therapeutic target for restoring mitochondrial FAO in MASLD.

  • Open Access

    Correction: The novel Chinese medicine JY5 formula alleviates hepatic fibrosis by inhibiting the notch signaling pathway

    by Yadong Fu, Zhun Xiao, Xiaoting Tian, Wei Liu, Zhou Xu, Tao Yang, Yonghong Hu, Xiaoxi Zhou, Jing Fang, Siqi Gao, et al.

  • Open Access

    Correction: Fuzheng Huayu formula ameliorates chronic cholestatic liver injury by upregulating PPARa in mice

    by Zheng Zhang, En-Qi Tang, Chun-Hui Li, Bi-Bi Wang, Yue Liang, Jin-Xin Lv, Gao-Feng Chen, Wei Liu, Yong-Ping Mu, Ping Liu, et al.

  • Fuzheng Huayu formula attenuates ductular reaction and liver fibrosis potentially through suppressing Gli1 pathway

    by Yonghong Hu, Zheng Zhang, Yue Liang, Enqi Tang, Bibi Wang, Wei Liu, Yongping Mu, Gaofeng Chen, Ping Liu, Jiamei Chen


  • Open Access

    Fuzheng Huayu formula ameliorates chronic cholestatic liver injury by upregulating PPARa in mice

    by Zheng Zhang, En-Qi Tang, Chun-Hui Li, Bi-Bi Wang, Yue Liang, Jin-Xin Lv, Gao-Feng Chen, Wei Liu, Yong-Ping Mu, Ping Liu, et al.

    Background: Fuzheng Huayu formula (FZHY) has been extensively applied in clinical for liver fibrosis treatment in China, its therapeutic potential in cholestatic liver injury remains underexplored. Objective: To evaluate the protective effects and underlying mechanisms of FZHY against chronic cholestatic liver injury. Methods: The therapeutic effect of FZHY was initially validated in a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced murine model of chronic cholestasis. Subsequent mechanistic investigations were conducted through comparative analyses in peroxisome proliferator-activated receptor α gene knockout ( Pparα −/− ) mice subjected to DDC challenge. Results: FZHY significantly ameliorated chronic cholestatic liver injury phenotypes in DDC-induced mice, as evidenced by bile acids (BAs) accumulation, inflammation, ductular reaction and biliary fibrosis was remarkably reduced after treatment with FZHY. Transcriptome sequencing analysis revealed that the effect of FZHY on chronic cholestatic liver injury was closely associated with activating PPAR signaling pathway and suppressing nuclear factor kappa-B (NF-κB) signaling. Further research found FZHY did not only enhance the total hepatic content of PPARα protein, but also increased its nuclear to cytoplasmic ratio that was reduced by DDC inducing. Additionally, FZHY suppressed hepatic phosphorylation of IκBα and NF-κB. The therapeutic effect of FZHY in treating DDC-induced mice with chronic cholestatic liver injury is similar to that of fenofibrate, a PPARα agonist. Crucially, genetic ablation of Pparα substantially abrogated the hepatoprotective and anti-fibrotic effects of FZHY in DDC-induced mice. Conclusions: The present study underscores FZHY regulated BAs metabolism and alleviated hepatic inflammation and fibrosis by upregulating PPARa in DDC-induced mice. Our study provides novel insights that FZHY might be a promising drug for chronic cholestatic liver injury. Graphical


  • Open Access

    Senkyunolide H potentiates bone marrow-derived mesenchymal stem cells therapy for liver cirrhosis by targeting MAEA to enhance ERK-driven HGF secretion

    by Yue Liang, Ying-Lin Zhang, Tian-Yu Cheng, Jia-Ying Pu, Zheng Zhang, Gao-Feng Chen, Wei Liu, Yong-Ping Mu, Jia-Mei Chen, Ping Liu


  • Rehmannioside D ameliorates hepatocyte apoptosis and liver fibrosis by suppressing Sirt7/p53 axis

    by Yue Liang, Tian-Yu Cheng, Jia-Ying Pu, Gao-Feng Chen, Wei Liu, Yong-Ping Mu, Hua Zhang, Jia-Mei Chen, Ping Liu


  • [Study on the mechanism of Fuzheng Huayu formula against biliary fibrosis in mice].

    by Z Zhang, Y Liang, E Q Tang, X X Zhou, Y H Hu, G F Chen, W Liu, Y P Mu, P Liu, J M Chen

    Objective: To investigate the effect and mechanisms of Fuzheng huayu formula (FZHY) on biliary fibrosis in mice. Methods: Mdr2 gene knowout (Mdr2-/-) mice were randomly divided into model group, FZHY-treated group and obeticholic acid (OCA)-treated group. Wide type C57BL/6J (WT) mice of the same age were used as the control group. Mdr2-/- mice were treated with the corresponding drugs by gavage from the first day of the 9th week old. The WT and model groups were given 0.3% sodium carboxymethyl cellulose by gavage, and the mice were sacrificed at the end of 12th week old. The activities of serum alkaline phosphatase (ALP) and alanine aminotransferase (ALT) were detected by high-speed biochemical analyzer. H&E staining and sirius red staining were used to observe the pathological changes of liver tissues. The hepatic hydroxyproline content was determined. The hepatic expressions of Col-Ⅰ and α-SMA, ductular reaction markers Epcam, CK7, CK19, and the expression of Pcna, Mki67 and Ccnd1; as well as the expression of inflammatory cytokines Ccl2, Ccl5, Tnf-α, Il10 and Cxcl4 were detected by immunohistochemical staining, western blot and qRT-PCR, respectively. Furthermore, the expression of PPARα and the phosphorylation NF-κB were detected by western blot. Results: Compared with WT mice, the serum ALT and ALP activities of Mdr2-/- mice were significantly increased (PPPPPMdr2-/- mice was significantly lower than that of WT mice, however the phosphorylation of NF-κB was significantly enhanced (PPMdr2-/- mice (PMdr2-/- spontaneous biliary fibrosis mice, and its mechanism was related to the regulation of PPARα/NF-κB pathway.


  • [Interventional effect of bone marrow mesenchymal stem cell transplantation with different doses of X-ray irradiation induced hepatic injury in mice].

    by Y Liang, L Luo, T Y Cheng, G F Chen, W Liu, Y P Mu, J M Chen, P Liu

    Objective: To investigate the interventional effect of bone marrow mesenchymal stem cell (BMMSC) transplantation with different doses of X-ray irradiation induced hepatic injury in mice. Methods: Eighteen female C57BL/6J mice were randomly divided into 0, 2, and 3 Gy irradiation groups and 0, 2, and 3 Gy transplantation groups. The irradiation group was used as the control and injected with an equal volume of culture medium. The mice in the transplantation group were irradiated with different doses of X-ray irradiation, and BMMSCs were intravenously infused into the bone marrow. The mice were sacrificed for sampling at the end of the 21st day. Mice body weight changes were recorded daily. The changes in the content of peripheral blood lymphocytes, red blood cells, platelets, and hemoglobin were detected by an automatic blood tester. The morphological changes in mice liver tissues were observed by hematoxylin-eosin staining. The serum activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected by a biochemical analyzer. The reduced glutathione contents in liver tissue were detected by the microplate method. The malondialdehyde content in liver tissue was detected by thiobarbituric acid. The content of total superoxide dismutase (T-SOD) in liver tissue was detected by the hydroxylamine method. The expression of the F4/80 protein in liver tissue was detected by the immunohistochemistry method. The protein expression of nuclear transcription factor erythroid 2 related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) in liver tissue was determined by the western blotting method. The mRNA expression of NLRP3, IL-6, and Nrf2 in liver tissue was detected by a real-time quantitative polymerase chain reaction. The multiple-group comparisons were analyzed by factorial analysis of variance. The inter-group comparisons were analyzed by the LSD method for statistical analysis. Results: The contents of peripheral blood lymphocytes, erythrocytes, platelets, and hemoglobin were significantly decreased in the 3 Gy irradiation group than the 0 Gy irradiation group (PPPPPPP<0.05). Conclusion: X-ray irradiation at a dose of 3 Gy can induce liver oxidative damage in mice. BMMSC transplantation can improve X-ray irradiation-induced liver oxidative damage in mice, and its mechanism of action may be related to the regulation of the Nrf2/HO-1 pathway.